Shanghai Ark Biopharmaceutical Co., Ltd.
Shanghai Ark Biopharmaceutical Co., Ltd.
Explore linked clinical trials.5 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 3 Study of Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis | idiopathic pulmonary fibrosis, interstitial lung disease, lung disorder, pulmonary fibrosis, respiratory system disorder | Not yet recruiting | Phase 3 | 2026-07-22 | NCT07719023 | |
| A Study of Ziresovir (AK0529) in High-risk Adult With Respiratory Syncytial Virus (RSV) Infection. | Infections, Mononegavirales infectious disease, Paramyxoviridae infectious disease, Pneumovirus Infections, RNA Virus Infections, cardiovascular disorder, heart disorder, respiratory syncytial virus infectious disease, viral infectious disease | Recruiting | Phase 2 / Phase 3 | 2026-06-22 | NCT07658534 | |
| A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AK0406 Injection in Healthy Adult Participants | Healthy Participants | Not yet recruiting | Phase 1 | 2026-02-25 | NCT07432698 | |
| A Clinical Study of AK0610 | Healthy Volunteer Study | Recruiting | Phase 1 | 2025-05-30 | NCT06996704 | |
| A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized Infants | Respiratory Synctial Virus Infections | Recruiting | Phase 3 | 2025-01-15 | NCT06775405 |